There are currently 161 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Lung Cancer participants are Ohio, California, Illinois and Michigan.
A Study of Mental Health Care in People With Cancer
NCT06037954
Recruiting
The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer (OD-C) approach. We will find out if the OD-C approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/09/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Register for Updates
Study of Trilaciclib and Lurbinectidin
NCT05578326
Recruiting
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire +1 locations
Conditions: Lung Cancer, Small-cell Lung Cancer
Register for Updates
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
NCT05587439
Recruiting
The purpose of this research study is to learn more about the inherited risk for developing lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases
Register for Updates
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
NCT07062172
Recruiting
This is a single-armed screening research study which screens immediate family member of lung cancer patients with a driver mutation to see if lung cancer can be inherited and whether researchers can find lung cancer early. Immediate family members of lung cancer patients will be 40-80 years old and screened using a low dose CT scan.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/02/2025
Locations: Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
Conditions: Lung Cancer, Driver Mutation
Register for Updates
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
NCT06145750
Recruiting
The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer Screening Test, FirstLook™ to practicing physicians affects overall lung cancer screening rates among their patients who are recommended and eligible for screening based on 2021 United States Preventive Services Task Force (USPSTF) but are not up to date with it. DELFI hypothesized that patients in the care of physicians or practice groups who have FirstLook™ w... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/01/2025
Locations: DARTNet Institute, Aurora, Colorado +2 locations
Conditions: Lung Cancer
Register for Updates
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
NCT05632809
Recruiting
To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
NCT00568490
Recruiting
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Head and Neck Cancer, Lung Cancer, Lip Cancer, Lip Neoplasms, Head and Neck Cancers
Register for Updates
Lung Cancer Biomarkers and Screening
NCT00301119
Recruiting
RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer. PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/25/2025
Locations: NYU Cancer Institute at New York University Medical Center, New York, New York
Conditions: Lung Cancer
Register for Updates
Study Assessing QBS72S For Treating Brain Metastases
NCT05305365
Recruiting
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Stanford Cancer Institute, Palo Alto, California
Conditions: Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California +34 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
NCT05845671
Recruiting
Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, increased activation of the erythroblastic leukemia viral oncogene homologue (ERBB) or cMet pathways appears to be a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure fr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: City of Hope Cancer Center, Duarte, California +3 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer
Register for Updates
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
NCT06580002
Recruiting
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2025
Locations: Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California
Conditions: Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer
Register for Updates